Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. - Wikidata - wikimedia - TriplyDB

Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort.

Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort.

http://www.wikidata.org/entity/Q44076014

about

A rational approach to single, dual and triple therapy in COPD COPD and its comorbidities: Impact, measurement and mechanisms A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease A review of the most common patient-reported outcomes in COPD--revisiting current knowledge and estimating future challenges New GOLD classification: longitudinal data on group assignment.Potential prognostic value of biomarkers in lavage, sputum and serum in a five year clinical follow-up of smokers with and without COPD Real-world characterization and differentiation of the Global Initiative for Chronic Obstructive Lung Disease strategy classification.The PLATINO study: description of the distribution, stability, and mortality according to the Global Initiative for Chronic Obstructive Lung Disease classification from 2007 to 2017.The effects of a telehealth coping skills intervention on outcomes in chronic obstructive pulmonary disease: primary results from the INSPIRE-II study Chronic obstructive pulmonary disease: respiratory review of 2014.Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial.Finding the best thresholds of FEV1 and dyspnea to predict 5-year survival in COPD patients: the COCOMICS study.The effect of comorbidities on COPD assessment: a pilot study Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines.Six-minute-walk distance and accelerometry predict outcomes in chronic obstructive pulmonary disease independent of Global Initiative for Chronic Obstructive Lung Disease 2011 Group.Evaluation of the COPD Assessment Test and GOLD patient types: a cross-sectional analysis.LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.Influence of pulmonary emphysema on COPD assessment test-oriented categorization in GOLD document.Physical Activity Characteristics across GOLD Quadrants Depend on the Questionnaire Used.Is COPD a Progressive Disease? A Long Term Bode Cohort Observation.A retrospective analysis to identify predictors of COPD-related rehospitalization.Lung function decline rates according to GOLD group in patients with chronic obstructive pulmonary disease Forecasting COPD hospitalization in the clinic: optimizing the chronic respiratory questionnaire.Characteristics and longitudinal progression of chronic obstructive pulmonary disease in GOLD B patients Differences in outcomes between GOLD groups in patients with COPD in the TIOSPIR(®) trial Biobehavioral Prognostic Factors in Chronic Obstructive Pulmonary Disease: Results From the INSPIRE-II Trial Predictive factors warrant screening for obstructive sleep apnea in COPD: a Taiwan National Survey Prognostic utility of the 2011 GOLD classification and other multidimensional tools in Asian COPD patients: a prospective cohort study.Investigating sensitivity, specificity, and area under the curve of the Clinical COPD Questionnaire, COPD Assessment Test, and Modified Medical Research Council scale according to GOLD using St George's Respiratory Questionnaire cutoff 25 (and 20) a A year in the life of German patients with COPD: the DACCORD observational study Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function.First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis.The use of health status questionnaires in the management of chronic obstructive pulmonary disease patients in clinical practice.The 2014 Updated GOLD Strategy: A Comparison of the Various Scenarios.Disease Modification in Emphysema Related to Alpha-1 Antitrypsin Deficiency.Efficacy of inhaled medications in asthma and COPD related to disease severity.How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Ob Comparing the 2007 and 2011 GOLD Classifications as Predictors of all-Cause Mortality and Morbidity in COPD.Prevalence and burden of dyspnoea among COPD patients in Japan.

P2860

Q26776477-0E4EAB9C-3117-42FF-ABA5-62F23AD0F2A5 Q26786812-2D96F5BD-94AF-4228-8284-55FBBABFF715 Q26801661-52356EF5-7808-4670-9097-4444B8A7E9EF Q26992071-F0D028C8-468E-47A2-AE69-7501247E8ADB Q30732307-51113125-1B30-4DCF-B0D3-6EAB1F3F9F1E Q33612752-C27E6DB5-65C3-4929-AC33-33633B252E6A Q33705840-C802FB5A-A5DE-4160-9500-91A7D96F381D Q33718748-B20DF7D8-3FF7-412E-BC21-2A6D47E21D8E Q34339200-DDE4444A-65F2-4C87-8721-A2E6555C13A4 Q34440060-DF4264E6-1CBA-452B-B8D2-D32E38C92DA1 Q34469716-20196E59-75BB-4C01-9CFE-105A4524FAA8 Q35108231-87CD1235-E16D-40A7-AEE0-6C2AEE996C5E Q35142397-B7BF8BC2-FA56-42EB-B63D-4D1B3DB9161C Q35538249-49641EB9-738C-4837-90CC-0CA1CB15EC74 Q35565089-E7636328-5290-44B8-84C4-516A134A8D6A Q35683840-A59E8CDA-0A67-4878-9CEA-E802520B96DD Q35703517-B6BF6A66-EAA5-4FEA-8379-C574212A04F0 Q35780996-36A65398-C510-4EC0-9415-69A91DD6C2D3 Q35956001-6DC597DE-7648-4243-AA6F-239436592CFB Q35996018-D314C577-98E4-422E-9C13-99E525F8EF66 Q36004028-5FDA92BD-4100-48FD-88AF-5245C5C30271 Q36052363-BFE85696-C585-4770-AAFF-8710D5FF1C60 Q36213141-28AE7D75-2AF2-42AD-8BD9-FE54CA43DB8C Q36285744-5E27CDC2-0FF0-4CC8-8E36-A53A395BB749 Q36498764-9B154277-6BF2-45CC-9133-E05E7B32342B Q36535142-88C3A6AF-A25E-4A02-A5FA-8F684A0767C8 Q36763590-F6478040-6A25-4DA5-9D63-8B893C851187 Q36858183-F1F30E5E-6096-4E5F-A0D3-79CB651DFC53 Q36926496-330E7C39-C797-4586-8B5A-3D95B795229F Q37123265-7C8F8005-B3CA-4BEC-9D95-B63B0B0B0A77 Q37141699-AD2298BD-BD87-4630-A8D9-9D92E9AB7CE9 Q37390146-52B31234-2E67-474B-9D83-D31FF6D47DF3 Q38217416-2552CE6D-35AF-4E08-B486-0574A3FFC958 Q38636062-EDF97B02-6C90-4547-A9FC-8369A74FE38C Q38832928-FB691F05-32F8-44AA-AEF4-631B15AB05F6 Q38862781-C74E2CC2-2871-48F9-BFD9-ED7FC7C0E794 Q39030602-9C5B3E5A-CC0D-4010-8CC0-0666168B75A1 Q39497381-31899C15-BA4E-4572-8C9C-8BEEFDF1494B Q39576261-59765972-F686-445A-9B81-0558C933F08D Q39616719-80FE1562-C97C-435E-A5EA-50308C5AB4C2

P2860

Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort.

http://www.wikidata.org/entity/Q44076014

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Characteristics, stability and ...... groups in the ECLIPSE cohort.

@en

Characteristics, stability and ...... groups in the ECLIPSE cohort.

@nl

type

label

Characteristics, stability and ...... groups in the ECLIPSE cohort.

@en

Characteristics, stability and ...... groups in the ECLIPSE cohort.

@nl

prefLabel

Characteristics, stability and ...... groups in the ECLIPSE cohort.

@en

Characteristics, stability and ...... groups in the ECLIPSE cohort.

@nl

P1433

Q44076014-F8D2A49B-4FD8-48C0-9386-2E7EBA4F0158

P1476

Q44076014-F74E6CCD-7E4A-437B-8F8B-3A82D410E214

P2093

Q44076014-2598B3B0-FFB6-4EB7-A7C0-A196424ECB2C

Q44076014-27D1EC79-468F-49FC-B007-340BC0B2CD31

Q44076014-30584FD1-DD5F-4E2A-AA04-B75182B7681C

Q44076014-443FDD6E-2418-4EB5-968F-2D343A838A91

Q44076014-4FACC721-2B37-4E48-8009-D5029DD2DBC0

Q44076014-5ECABB39-F44D-4DFA-A85E-3BE7C5787D36

Q44076014-77F253D2-01B0-4F02-B221-F873D061687B

Q44076014-7F97C066-5D3F-4BDC-BFF0-FE3B424160E4

Q44076014-907BE739-14B4-4DF0-8A30-95F0C1AC3F9E

Q44076014-BDB832A4-15C2-4B3A-8E51-4F1976C520AD

P304

Q44076014-75A2DFB8-7C5B-424F-82C5-1D1364124C2F

P31

Q44076014-581A8CF0-68CF-4322-A04D-EBE38FA74489

P356

Q44076014-56A04E44-DA36-462C-8437-03B03EC5AABE

P433

Q44076014-0B06A74B-2ED0-4D3E-9E6C-FF84A9EE1C09

P478

Q44076014-85710882-123E-41A5-9195-C5425DE71A4F

P50

Q44076014-7FA2D3F4-B403-4904-AACF-23FC40E7B08E

Q44076014-9711F0F6-C517-4FB6-9996-4B96A8D80CAD

Q44076014-A091313A-814D-4781-8E32-742050D86F55

Q44076014-D7EB42E2-8065-4894-AD0C-98884E07A291

P577

Q44076014-BAAAEE28-FB3A-42A0-9CFD-EAA44D3C70EC

P5875

Q44076014-39495217-68DB-488D-B530-32A99871A345

P698

Q44076014-F525A7C4-05EE-4C47-8D20-51FA4C2289DE

P921

Q44076014-9709CAAB-1753-40C8-8004-481AF82A3C15

P356

09031936.00195212

P1433

European Respiratory Journal

P1476

Characteristics, stability and ...... groups in the ECLIPSE cohort.

@en

P2093

Alvar Agusti

http://www.w3.org/2001/XMLSchema#string

Bartolomé Celli

http://www.w3.org/2001/XMLSchema#string

Bruce E Miller

http://www.w3.org/2001/XMLSchema#string

Courtney Crim

http://www.w3.org/2001/XMLSchema#string

David A Lomas

http://www.w3.org/2001/XMLSchema#string

ECLIPSE Investigators

http://www.w3.org/2001/XMLSchema#string

Hana Müllerova

http://www.w3.org/2001/XMLSchema#string

Harvey O Coxson

http://www.w3.org/2001/XMLSchema#string

Julie C Yates

http://www.w3.org/2001/XMLSchema#string

Lisa D Edwards

http://www.w3.org/2001/XMLSchema#string

P304

636-646

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1183/09031936.00195212

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P50

Ruth Tal-Singer

Emiel F M Wouters

P577

2013-06-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262043826

http://www.w3.org/2001/XMLSchema#string

P698

23766334

http://www.w3.org/2001/XMLSchema#string

P921

chronic obstructive pulmonary disease